The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of β-carotene in healthy volunteers

Journal of Clinical Pharmacology

Volumn 36, Issue 2, 1996, Pages 152-159

  Zhi, Jianguo ^a   Melia, Angela T ^a   Koss Twardy, Susan G ^a   Arora, Sujata ^a   Patel, Indravadan H ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BETA CAROTENE; ENZYME INHIBITOR; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG SCREENING; FAT INTAKE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OBESITY; ORAL DRUG ADMINISTRATION; VITAMIN DEFICIENCY; VITAMIN INTAKE; VOLUNTEER;

EID: 0029989469     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04180.x     Document Type: Article

References (19)

1. Bendich A: Clinical importance of beta carotene. Perspect Appl Nutr 1993;1:14-22.
2. Roche Laboratories: Solatene: beta-carotene capsules. In, Physician's Desk Reference. Montvale, NJ: Medical Economics Data Production Company, 1995.
3. Hadváry P, Lengsfeld H, Wolfer H: Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J 1988;256:357-361.
4. Borgström B: Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochem Biophys Acta 1988;962:308-316.
5. Fernandez E, Borgström B: Effects of tetrahydrolipstatin, a lipase inhibitor, on absorption of fat from the intestine of the rat. Biochem Biophys Acta 1989;1001:249-255.
6. Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB, Patel IH: Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994;56:82-85.
7. Marzo A, Rescigno A: Pharmacokinetics of endogenous substances: some problems and some solutions. Eur J Drug Metab Pharmacokin 1993;18:77-88.
8. Grizzle JE: The two-period change-over design and its use in clinical trials. Biometrics 1965;21:467-480.
9. Grizzle JE: Corrections to "The two-period change-over design and its use in clinical trials." Biometrics 1974;30:727.
10. Drent ML, van der Veen EA: Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes 1993;17:241-244.
11. Hauptman JB, Jeunet FS, Hartmann D: Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992;55:3095-3135.
12. Tonstad S, Pometta D, Erkelens DW, Ose L, Moccetti T, Schouten JA, et al: The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994;46:405-410.
13. Drent ML, Larsson I, William-Olsson T, Quaade F, Czubayko F, von Bergmann K, et al: Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes 1995;19:221-226.
14. Tangney CC, Shekelle RB, Raynor W, Gale M, Betz EP: Intra-and interindividual variation in measurements of β-carotene, retinol, and tocopherols in diet and plasma. Am J Clin Nutr 1987;45: 764-769.
15. Johnson EJ, Russell RM: Distribution of orally administered β-carotene among lipoproteins in healthy men. Am J Clin Nutr 1992;56:128-135.
16. Brown ED, Micozzi MS, Craft NE, Bieri JG, Beecher G, Edwards BK, et al: Plasma carotenoids in normal men after a single ingestion of vegetables or purified β-carotene. Am J Clin Nutr 1989;49:1258-1265.
17. Nierenberg DW, Stukel TA, Baron JA, Dain BJ, Greenberg ER, and The Skin Cancer Prevention Study Group: Determinants of increase in plasma concentration of β-carotene after chronic oral supplementation. Am J Clin Nutr 1991;53:1443-1449.
18. Constantino JP, Kuller LH, Begg L, Redmond CK, Bates MW: Serum level change after administration of a pharmacologic dose of β-carotene. Am J Clin Nuir 1988;48:1277-1283.
19. Zhi J, Melia AT, Eggers H, Joly R, Patel IH: Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995;35:1103-1108.